Evidence

How to Get Started in Research as a Primary Care Professional in the UK

What your heart failure register is not telling you

Coding, registers and the four pillars in UK primary care

Falling blood pressure and BMI in T2D may signal early dementia

Semaglutide for secondary cardiovascular prevention: An update that may have gone unnoticed – what NICE TA1152 means for primary care

NICE TA1152 establishes semaglutide 2.4 mg as a secondary cardiovascular-prevention treatment for adults with established cardiovascular disease and a BMI of at least 27 kg/m². Niraj Lakhani considers what this means for primary care.

The no-biopsy pathway has arrived, and it stops at the surgery door

FIVE questions to ask before you switch to ambient AI

MASH: where the field is heading, and where primary care starts

New MASH licences clarify the fibrosis stages they cover, while the staging pathway remains the practical question for primary care.

State of Child Health 2026

Chronic Kidney Disease in Primary Care: Small Changes That Make a Big Difference

CKD is common, but progression is not inevitable.

Biggest weight loss, biggest trade-off?

A BMJ network meta-analysis of 262 trials and 99,791 participants compares 19 obesity drugs. The ranking matters less than what sits behind each position.

BMI and type 2 diabetes: how much do ethnicity, age, and sex matter?

Unseen in primary care: how patients with complex mental health difficulties experience accessing help

Around a quarter of patients presenting to primary care with mental health difficulties meet criteria for personality disorder, yet only 1 to 1.5% have a coded diagnosis. A new qualitative study explores what that gap looks like from the patient side.

Primary Care Research: From an Optional Extra to an Essential Part of Modern General Practice

Almost 90% of NHS patient contacts happen in primary care, yet most research still happens somewhere else. Dr Fatima Tahir on why that gap matters, and what practices stand to gain from closing it.

Finerenone may slow kidney decline in glomerular disease

A prespecified exploratory analysis of the FIND-CKD trial reports slower eGFR decline with finerenone in chronic kidney disease due to glomerular diseases.

Finerenone gets NICE backing for HFpEF and HFmrEF: what the final draft guidance means for primary care

NICE has published final draft guidance recommending finerenone (Kerendia) for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. With nearly 280,000 people in England potentially eligible, this is a significant moment for a patient group with few disease-modifying options.

Triglyceride-associated cardiovascular risk: Leaving risk on the table

Despite excellent LDL-cholesterol management, 1 in 3 patients with established ASCVD will experience a recurrent event within three years. Elevated triglycerides represent a major — yet frequently overlooked — driver of residual cardiovascular risk. Moudy Khodadi, Advanced Pharmacist Lipid Clinic, explains the mechanism, the evidence, and what actually works.

One patient, three pains: a palliative care case study in opioid titration

This week, our expert insights will guide you through a case study from Jan Brassington’s webinar, ‘Managing Pain in Palliative Care.’ You can now watch it as an on-demand video on our CPD Webinars page!

MASLD is not just a man's disease

Most of us carry a mental model of fatty liver disease as something that turns up more often in men. A new narrative review in Diabetologia suggests it's time for an update.

Appraising the Longevity Supplement Stack with the Latest Evidence

Patients are arriving in clinic with curated supplement stacks, convinced that longevity science has delivered a shortcut to a longer, healthier life. The evidence tells a more sobering story.

How much does HPV vaccination reduce cervical cancer mortality?

From PCOS to PMOS: A Practical Update for GPs

PCOS has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following international consensus in 2026. This expert update covers the new diagnostic criteria, holistic management approach, and what this means for primary care.

Three receptors, one molecule: how triple agonists work

A triple agonist is a single peptide with activity at the GLP-1, GIP and glucagon receptors. This animation maps where each one acts and what the early trial evidence shows.

Fish oil and dementia prevention: what a new high-dose DHA trial found

A new randomised trial (PreventE4) confirmed that high-dose DHA supplementation reaches the brain — even in APOE ε4 carriers — but found no measurable benefit on hippocampal volume, cortical thickness, or cognitive scores over 24 months.

GLP-1 Prescribing Is Now a Minefield. Here's a Practical Route Through It

Three NICE pathways for the same class of drug, each with its own eligibility criteria, funding route, and stopping rule. Kashif Shakoor maps a practical route through the complexity.